Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Marinus Pharmaceuticals (MRNS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.11 | $27.00 | $2.00 | 541.55% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Marinus Pharmaceuticals comes to $9.11. The forecasts range from a low of $2.00 to a high of $27.00. The average price target represents an increase of 541.55% from the last closing price of $1.42.
Analyst Price Targets (9 )
Broker Rating
Marinus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.55 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.27 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy, representing 72.73% of all recommendations. A month ago, Strong Buy made up 81.82%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 9 | 9 | 9 |
Buy | 0 | 0 | 1 | 1 | 1 |
Hold | 3 | 3 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.55 | 1.55 | 1.27 | 1.27 | 1.27 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/16/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Hold |
4/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
3/26/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
3/6/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
3/5/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
3/1/2024 | LadenburgThalmann | Michael Higgins | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.55 |
ABR (Last week) | 1.55 |
# of Recs in ABR | 11 |
Average Target Price | $9.11 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.68 |